Preview

Пульмонология

Расширенный поиск

Легочные побочные действия, вызываемые антиревматическими препаратами

Об авторах

Ю. В. Муравьев
Институт ревматологии РАМН
Россия

Москва



И. А. Удельнова
Институт ревматологии РАМН
Россия

Москва



Список литературы

1. Княжеская Н.П. Аспириновая бронхиальная астма. Рус. мед. журн. 1998; 6 (23): 1478-1481.

2. Кристал Р.Дж. Интерстициальные заболевания легких. В кн.: Браунвальд Е., К.Дж. Иссельбахер, Р.Г. Петередорфа и др. (ред.) Внутренние болезни: Пер. с англ. М.: Медицина; 1995; кн. 6: 146.

3. Aglas R., Rainer F., Hermann J. et al. Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis. Arthr. and Rheum. 1995; 38: 291-292.

4. Alarcon G.S., Gispen J.G., Koopman W.J. Severe reversible interstitial pneumonitis induced by low dose methotrexate (letter). J. Rheumatol. 1989; 16: 1007-1008.

5. Anderson R.J., Potts D.E., Gabow P.A. et al. Unrecognized adult salicylate intoxication. Ann. Intern. Med. 1986; 85: 745-748.

6. Austr. ADR Bull. 1995; 14: 1. Цит. по: Безопасность лекарств. Экспресс-информ. 1997; 1: 15-16.

7. Averbuch М., Halpern Z., Hallak A. et al. Sulfasalazine pneumonitis. Am. J. Gastroenterol. 1985; 80: 343-345.

8. Barrera P., van Ede A., Laan R.F. et al. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis: cluster of cases in a period of three months. Ann. Rheum. Dis. 1994; 53: 479-480.

9. Bedrossian C.W.M., Miller W.C., Luna M.A. Methotrexateinduced diffuse interstitial pulmonary finrosis. South. Med. J. 1979; 72: 313-318.

10. Bekerman C., Hoffer P., Betran J., Guipta R. Gallium-67 citrate imaging studies of the lung. Semin. Nucl. Med. 1980; 3: 286-301.

11. Bell M.J., Geddie W.R., Gordon D.A., Reynolds W.J. Preexisting lung disease in patients with rheumatoid arthritis may predispose to methotrexate lung (abstract). Arthr. and Rheum. 1986; 29 (suppl. 4): S75.

12. Briggs W.A., Johnson J.P., Teichman S et al. Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome. Medicine (Baltimore) 1979; 58: 348.

13. Broderick T.V., Reinke R.T, Goldman E. Salicylate-induced pulmonary edema. Am. J. Roentgenol. 1976; 127: 865-866.

14. Buron G.H. Rash and pulmonary eosinphillia associated with fenbufen. Br. Med. J. 1990; 300: 82-83.

15. Buscaglia A.J., Cowden F., Brill H. Pulmonary infiltrates associated with naproxen. J.A.M.A. 1984; 251: 65-66.

16. Cannon G.W., Ward J.R., Clegg D.O. et al. Acute lung disease associated with low-dose pulce methotrexate therapy in patients with rheumatoid arthritis. Arthr. and Rheum. 1983; 26: 1269-1274.

17. Cannon G.W., Reading J.C., Ward J.R. et al. Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate. Scand. J. Rheumatol. 1990; 19: 285-294.

18. Carroll G.J., Thomas R., Phatouros C.C. et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J. Rheumatol. 1994; 21: 51-54.

19. Chuck A.J., Wilcox M., Bossingham D.H. Fenbufen-associated pnemonitis. Br. J. Rheumatol. 1985; 24: 302-305.

20. Cook N.J., Carroll G.J. Successful réintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann. Rheum. Dis. 1992; 51: 272-274.

21. Cooke N .T., Bamji A.N . Gold and pulmonary function in rheumatoid arthritis. Br. J. Rheumatol. 1983; 22: 18-21.

22. Cooper J.A.D., White D.A., Matthay R.A. State of the art: Drug-induced pulmonary disease. Part 1. Cytotoxic drugs. Am. Rev. Respir. Dis. 1986; 133: 321-340.

23. Cooper A.D., White D.A., Matthay R.A. Drug induced pulmonary disease. Part 2. Non-cytotoxic drugs. Ibid. 488-505.

24. Costabel U., Schmitz-Schumann M., Guzman J. et al. Goldinduced fibrosing alveolitis. Dtsch. Med. Wschr. 1985; 110: 1162-1166.

25. Davies D., MacFarlane A. Fibrosing alveolitis and treatment with sulphasalazine. Gut 1974; 15: 185-188.

26. Declauux B., Whitelaw W.A., Derenne J.P. Methotrexate and asthma (letter). Chest 1993; 103: 1307-1308.

27. Elasser S., Dalquen P., Soler M., Perruchoud A.P, Methotrexate-induced pneumonitis: appearance four weeks after discontinuation of treatment. Am. Rev. Respir. Dis. 1989; 140: 1089-1092.

28. Engelbrecht J.A., Calhon S.L., Sheerer J.J. et al. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthr. and Rheum. 1983; 26: 1275-1278.

29. Epier G.R., Snider G.L., Gaensler E.A. et al. Bronchiolitis and bronchitis in connective tissue disease. A possible relationship to the use of penicillamine. J.A.M.A. 1979; 242: 528-532.

30. Evans R.B., Ettensohn D.B. Fawaz-Estrup F. et al. Gold lung: Recent developments in pathogenesis, diagnosis, and therapy. Semin. Arthr. Rheum. 1987; 16: 196-205.

31. Fein M. Sulindac and pneumonitis. Letter. Ann. Intern. Med. 1981; 95: 245.

32. Fink S.D., Kremer J.M. Successful treatment of interstitial lung disease in systemic lupus erythematosus with methotrexate. J. Rheumatol. 1995; 22: 967-969.

33. Frank S .T., Weg J.G., Harkleorad L.E., Fitch R.F. Pulmonary disfunction in rheumatoid disease. Chest 1973; 63: 27-33.

34. Furst D.E., Ericson N., Clute L. et al. Adverse experience with methotrexate during 176 weeks of a long term prospective trial in patients with rheumatoid arthritis. J. Rheumatol. 1990; 17: 1628-1635.

35. Garcia J.G .N ., Munim A., Nugent K.M. et al. Alveolar macrophage gold retention in rheumatoid arthritis. Ibid. 1987; 14: 435-438.

36. Geddes D.M., Corin B., Brewerton D.A. et al. Progressive airway obliteration in adults and association with rheumatic disease. Quart. J. Med. 1977; 184: 427-444.

37. Golden M .R., Katz R.S., Balk R.A., Golden H.E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J. Rheumatol. 1995; 22: 1043-1047.

38. Gonzales E.B., Truslow W., Miller S.B ., Agudelo C.A. Smoking and underlying lung disease are not contraindications to methotrexate therapy (abstract). Arthr. and Rheum. 1993; 36 (suppl.9): S81.

39. Gosink B.B., Freidman P.J., Liebow A.A. Bronchiolitis obliterans. Roentgenologic-pathologic correlation. Am. J. Roentgenol. 1973; 117: 816-832.

40. Green L., Schattner A., Berkenstadt H. Severe reversible interstitial pneumonitis induced by low dose methotrexate: report of case and review of literature. J. Rheumatol. 1988; 15: 110-112.

41. Hargreaves M .R., Movat A.G., Benson M.K. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992; 47: 628-633.

42. Hassan W., Carpenter M ., Kelly C. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis (letter). Ibid. 1993; 48: 191.

43. Hasselrnann M., Maurier F., Lutun P.H. et al. Syndrome de goodpasture au cours d'une polyarthrite rheumatoide par la dpenicillamine. Rev. Med. Int. 1982; 70: 237-238.

44. Heffner J.E., Sahn S.A. Salicylate-induced pulmonary edema. Clinical features and prognosis. Ann. Intern. Med. 1981; 95: 405-409.

45. Howard-Lock H.E., Lock C.J.L., Meura A. et al. D-penicillamine: Chemistry and clinical use in rheumatoid disease. Semin. Arthr. Rheum. 1986; 15: 261-281.

46. Hrnicek G., Skelton J., Miller W.C. Pulmonary edema and salicylate intoxication. J.A.M.A. 1974; 230: 866-867.

47. Hyland R.H., Gordon D.A., Broder I. et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J. Rheumatol. 1983; 10: 395-405.

48. Jansen H.M., Elema J.D., Hylkema B.S. et al. Progressive obliterative bronchiolitis in a patient with rheumatoid arthritis. Eur. J. Respir. Dis. 1982; 63 (suppl.121): 43-52.

49. Jones G., Mierins E., Karish J. Methotrexate-induced asthma. Am. Rev. Respir. Dis. 1991; 143: 179-181.

50. Juhl J.H. Paul and Juhl's essentials of roentgen interpretation. Philadelphia: Harper & Row Publishers Inc.; 1981. 988-989.

51. Kaplan R.L., Waite D.H. Progressive interstitial lung disease from prolonged methotrexate therapy. Arch. Dermatol. 1978; 114: 1800-1802.

52. Katzenstein A.A., Askinn F.B. Surgical pathology of non-neoplastic lung disease. Philadelphia: W.B.Saunders; 1982. 108-112.

53. Kerstens P.J.S.M., van Loenhout J.W.A., Boerbooms A.M .T. et al. Methotrexate, pneumonitis, and infection (letter). Ann. Rheum. Dis. 1992; 51: 1179.

54. Khalil H., Molinary E., Stoller J.K. Diclofenac (Voltaren)- induced eosinophilic pneumonitis. Arch. Intern. Med. 1993; 153: 1649-1652.

55. Kremer J.M., Petrillo G.F., Hamilton R.A. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J. Rheumatol. 1995; 22 (l): 38-40.

56. Kremer J.M., Alarcon G.S., Weinblatt M.E. et al. Clinical, laboratory, radiographic and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. Arthr. and Rheum. 1997; 40 (10): 1829-1837.

57. Kudo K., Miyamoto J., Horruchi Y. One case of pulmonary fibrosis occurring during therapy and a review of the chest x-rays of asthmatic patients. Jpn J. Thorac. Dis. 1977; 15: 646-652.

58. Law K.F., Aranda C.P., Smith R.L. et al. Pulmonary cryptococcosis mimicking methotrexate pneumonitis. J. Rheumatol. 1993; 20: 872-873.

59. Leduc D., De Vuyst P., Lhereux P. et al. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis: discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 1993; 104: 1620-1623.

60. Lee R.P., King E.G., Russel A.S. lbuprofen: A severe systemic reaction. Can. Med. Assoc. J. 1983; 29: 854-855.

61. Leino R., Liippo K., Ekfors T. Sulfasalazine-induced reversible hypersensitivity pneumonitis and fatal fibrosing alveolitis: report of two cases. J. Intern. Med. 1991; 229: 553-556.

62. Levinson M .L., Lynch J.P., Bower J.C. Reversal of progressive, life threatening gold hypersensitivity pneumonitis by corticosteroids. Am. J. Med. 1981; 71: 908-912.

63. Line B.R., Hunninghake G.W., Keogh B.A. et al. Gallium-67 scanning to stage the alveolitis of sarcoidosis; correlation with clinical studies, pulmonary function studies and bronchoalveolar lavage. Am. Rev. Respir. Dis. 1981; 123: 440-446.

64. Lippmann M. Pulmonary reactions to drugs. Med. Clin. N. Am. 1977; 61: 1353-1367.

65. Louie S., Gamble C.N., Cross C.E. Penicillamine-associated pulmonary hemmorrhage. J. Rheumatol. 1986; 13: 963-966.

66. Louie S., Lilington G.A. Low dose methotrexate pneumonitis in rheumatoid arthritis. Thorax 1986; 41: 703-704.

67. McCormick J.N., Wood P., Bell D. Penicillamine-induced Goodpasture's syndrome. In: Penicillamine research in rheumatoid disease. Oslo: Fabritius and Sonner; 1977. 132-138.

68. McKendry R.J.R., Cyr M. Toxiticy of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case control of 131 patients. Arch. Intern. Med. 1989; 149: 685-689.

69. Moseley R.H., Barwick K.W., Dobuler K., DeLuca V.A.Jr. Sulfasalazine-induced pulmonary disease. Dig. Dis. Sci. 1985; 30: 901-914.

70. Mulhierin D., Cummiskey J.M., Doyle G.D., Fitzgerald O. Methotrexate pneumonitis in rheumatoid arthritis — a dramatic response to treatment. Br. J. Rheumatol. 1992; 31: 356-357.

71. Murphy K.C., Atkins C.J., Offer R.C. et al. Obliterative bronchiolitis in two rheumatoid arthritis patients treated with penicilamme. Arthr. and Rheum. 1981; 24: 557-560.

72. Nader D.A., Schillaci R.F. Pulmonary infiltrates with eosinophilia to naproxen. Chest 1983; 83: 280-282.

73. Newman E.D., Harrington T.M. Fatal methotrexate pneumonitis in rheumatoid arthritis (letter). Arthr. and Rheum. 1988; 31: 1585-1586.

74. Park G.D., Spector R., Headstream T., Goldberg M. Serious adverse reactions associated with sulindac. Arch. Intern. Med. 1982; 142: 1292-1294.

75. Partanen J., van Assendelft A.H .W ., Koskimies S. et al. Patients with rheumatoid arthritis and gold-induced pneumonitis express two high-risk mayor histocompatibility complex patterns. Chest 1987; 92: 277-281.

76. Peces R., Riesa J.R., Arboleya L.R. et al. Goodpasture's syndrome in patient receiving penicillamine and carbamimle. Nephron 1987; 45: 316-320.

77. Perruquet J.L., Harrington T.M., Davis D.E. Pneumocystis carnii pneumonia following methotrexate therapy for rheumatoid arthritis (letter). Arthr. and Rheum. 1983; 26: 1291-1292.

78. Pourel J., Guillemin F., Fener P. et al. Delayed methotrexate pneumonitis in rheumatoid arthritis (letter). J. Rheumatol. 1991; 18: 303-304.

79. Reid J., Watson P.D., Sproull D.H. The mode of action of salicylate in acute rheumatic fever. Quart. J. Med. 1950; 19: 1-19.

80. Ridley M.G., Wolfe C.S., Mathews J.A. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann. Rheum. Dis. 1988; 47: 784-788.

81. Roenigk H.H., Auerbach R., Maibach H.I., Weinstein G.D. Methotrexate guidelines-revised. J. Am. Acad. Dermatol. 1982; 6: 145-155.

82. Rosenow E.C. The spectrum of drug-induced pulmonary disease. Ann. Intern. Med. 1972; 77: 977-991.

83. Savihalti M. Pulmonary complications following the use of gold salts, Ann. Med. Interne Fen. 1948; 37: 263-266.

84. Schwartz G.F., Richter C., Bauerfeind S., Gross W.L. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997; 52: 377-319.

85. Schwartz G.F., Anderson S.T. Methotrexate induced pneumonitis in a young woman with psoriasis and rheumatoid arthritis (letter). J. Rheumatol. 1990; 17: 980.

86. Scott D.L., Bradby G.V.H., Altman T.J. et al. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann. Rheum. Dis. 1981; 40: 136-141.

87. Scully C.J., Andersen C.J., Cannon G.W. Long-term methotrexate therapy for rheumatoid arthritis. Semin. Arthr. Rheum. 1991; 20: 317-331.

88. Searles G., McKendry J.R. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and review of the literature. J. Rheumatol. 1987; 14: 1164-1171.

89. Sheehan N.J. Pulmonary infiltrates and eosonophilia associated with naproxen. Br. J. Rheumatol. 1985; 24: 302-305.

90. Shettar S.P., Chattupadhyay C., Wolstenholme R.J. et al. Diffuse alveolitis on a small dose of penicillamine. Ibid. 1984; 23: 220-224.

91. Singerland R., Hoogsteden H.C., Adriaansen H.J. et al. Goldinduced pneumonitis. Respiration 1987; 52: 232-236.

92. Smith F.E., Lindberg P.J. Life-threatening hypersensitivity to sulindac. J. A. M. A. 1980; 244: 269-270.

93. Sostman H.D., Mathay R.A, Putman C.T. et al. Methotrexateinduced pneumonitis. Medicine (Baltimore) 1976; 55: 371-388.

94. Sprung D.J. Sulifidac causing a hyersensitivity reaction with peripheral and mediastinal lymphadenopathy. Ann. Intern. Med. 1998; 97: 564.

95. Stemlieb I., Fisher М ., Scheinberg I.H. D-penicillamineinduced Goodpasture's syndrome in Wilson's disease. Ibid. 1983; 82: 673-676.

96. Stenger A.A., Houtman F.M., Bruyn G.A. et al. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand. J. Rheumatol. 1994; 23: 51-53.

97. Sullivan S.N . Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate. J. Clin. Gastroenterol. 1987; 9: 461-463.

98. Takimoto C.H., Lynch D., Stulberg M .S. Pulmonary infiltrates associated with sulindac therapy. Chest 1990; 97: 230-232.

99. Thomas P., Seaton A., Edvards J. Respiratory disease due to sulphasalazine. Clin. Allergy 1974; 4: 41-47.

100. Thurston J.G., Marks P., Trapnel D. Lung changes associated with phenylbutasone treatment (letter). Br. Med. J. 1976; 2: 1422-1423.

101. Van der Veen M.J., Dekker J.J., Diant J.D. et al. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J. Rheumatol. 1995; 22: 1766-1768.

102. Weber J.C.P., Essigmen W.K. Pulmonary alveolitis and NSAID-fact or fiction? (letter). Br. J. Rheumatol. 1986; 25: 5-6.

103. Weinblatt M.E., Coblin J.C., Fox D.A. et al. Efficacy of lowdose pulse methotrexate in rheumatoid arthritis. N. Engl. J. Med. 1985; 312: 118-122.

104. Weinstein A., Marlowe S., Korn J. et al. Low dose methotrexate treatment of rheumatoid arthritis. Long-term observations. Am. J. Med. 1985; 79: 331-337.

105. Winterbauer R.H., Wilske K.R., Wheelis R.F. Diffuse pulmonary injury associated with gold treatment. N. Engl. J. Med. 1976; 294: 919-921.

106. Wollner A., Mohle-Boetani J., Lambert R.E. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax 1991; 46: 205-207.

107. Yamacado S., Yoshida Y., Yamada T. et al. Pulmonary infiltration and eosinophilia associated with sulfasalazine therapy for ulcerative colitis: a case report and review of literature. Intern. Med. 1992; 31: 108-113.


Рецензия

Для цитирования:


Муравьев Ю.В., Удельнова И.А. Легочные побочные действия, вызываемые антиревматическими препаратами. Пульмонология. 2003;(4):108-114.

For citation:


Muraviev Yu.V., Udelnova I.A. Adverse effects on the lung caused by anti-rheumatic drugs. PULMONOLOGIYA. 2003;(4):108-114. (In Russ.)

Просмотров: 119


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)